United States

Head-to-head Farm Trials Prove Effectiveness of FACTREL® Injection

Producers can confidently rely on this reproduction tool to improve breeding efficiency

FLORHAM PARK, N.J., Oct. 20, 2015 — Three on-farm studies of more than 12,000 cows showed FACTREL® Injection (gonadorelin injection), when used with LUTALYSE® Injection (dinoprost injection), effectively helped synchronize estrous cycles and achieve equivalent conception risks as compared with other on-farm fixed-time artificial insemination (AI) protocols in lactating dairy cows.

One of those studies, the dairy industry’s largest fixed-time AI non-inferiority study to date involving 5,827 cows, showed FACTREL was not statistically different when used in fixed-time AI protocols as compared to competitive GnRH products containing gonadorelin diacetate tetrahydrate. The first-service conception risk in cows treated with FACTREL was noninferior to farm protocols using competitive GnRH products. In addition, there was no significant difference (P=0.65) in first-service conception risk between those treated with a 2-mL dose of FACTREL (37.6%) and those treated with farm protocols using competitive products (39%).1

In a second and independent study of 3,938 cows, the conception risk of animals treated with a 2-mL dose of FACTREL was not statistically different (P>0.10) to those treated with Cystorelin® (gonadorelin diacetate tetrahydrate) in a fixed-time AI program.2

A third and independent study of 2,620 cows from 40 Canadian herds, found no difference (P=0.84) in first-time conception risk between its two study groups. Furthermore, FACTREL was found to be noninferior to Fertiline® (gonadorelin acetate) in a fixed-time AI protocol.3

Conception Risk (%) Reported in Recently Published Studies
Trial
Total Observations (n)
Conception Risk (%)
FACTREL®
Other GnRH product
p-value
  FTAI using FACTREL or current farm protocol1
5,827
37.6
39.0
= 0.65
  FTAI using FACTREL or Cystorelin® 2
3,938
36.0
37.0
> 0.10
  FTAI using FACTREL or Fertiline® 3
2,620
40.4
41.0
= 0.84


“Using FACTREL and LUTALYSE in combination provides an effective, U.S. Food and Drug Administration (FDA)-approved method of synchronizing estrus using a variety of fixed-time AI programs,” said Ken Learmont, DVM, senior veterinarian, Dairy Technical Services, Zoetis. “With more than 12,000 combined cows studied, producers can have the peace of mind that FACTREL is a safe and efficacious product when used according to its label.”

FACTREL now offered in a larger, more convenient vial size
Zoetis continues to focus on convenience for producers by now offering FACTREL in a 50-mL vial size. The larger bottle size delivers ease by allowing producers to treat up to 25 cows per bottle, which is more than most other GnRH products on the market.


For the convenience of producers, Zoetis is now offering FACTREL® Injection (gonadorelin injection) in a 50-mL vial size.

With approved use of Zoetis products for fixed-time AI, customers can use LUTALYSE and FACTREL in many of the synchronization protocols recommended by the Dairy Cattle Reproduction Council. The FDA approval of FACTREL and LUTALYSE includes a flexible schedule and the only flexible dose of a GnRH product, allowing producers to develop protocols that fit their dairy’s needs.

Ken Mitchell, DVM, of Valley Veterinarians based in Tulare, California, expressed confidence in FACTREL: “We were involved in a trial to test the efficacy of FACTREL used in a simple timed AI sequence. At the end of the trial, as a whole, our reproductive program on this dairy became noticeably more efficient during that period of time.”

Committed to reproductive success
Raising the bar in dairy reproduction requires a team effort. Zoetis understands the changing needs of today’s dairy industry and is committed to providing flexible, comprehensive on-label solutions that are consistent with management practices.

“This new offering is a continuation of Zoetis’ commitment to providing the industry with comprehensive reproductive management solutions,” Dr. Learmont said. “We’ll continue to invest in new, practical and on-label solutions and research that will help improve reproduction so veterinarians and producers can use them with confidence. This provides producers the peace of mind they are doing the right thing for their dairy.”

For more than 30 years, as the leader in dairy reproduction research, support and technical services, Zoetis has been delivering innovations to help producers and veterinarians improve reproductive programs.

To learn more about FACTREL and LUTALYSE as an on-label synchronization program, visit DairyReproSolutions.com or contact your veterinarian or Zoetis representative.

IMPORTANT SAFETY INFORMATION FOR FACTREL: FACTREL Injection is for use in cattle only. Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION FOR LUTALYSE: Women of childbearing age and persons with respiratory problems should exercise extreme caution when handling LUTALYSE. LUTALYSE is readily absorbed through the skin and may cause abortion and/or bronchiospasms, therefore spillage on the skin should be washed off immediately with soap and water. Aseptic technique should be used to reduce the possibility of post-injection clostridial infections. Do not administer LUTALYSE in pregnant cattle unless cessation of pregnancy is desired. See full Prescribing Information.

About Zoetis
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetisUS.com.

For Further Information,Contact :

Jillian Spector
Zoetis
973-443-2847
jillian.spector@zoetis.com

Kristina Hopkins
Bader Rutter
262-938-5577
khopkins@bader-rutter.com

1 Data on File, Study Report No. 13PETREPRO01-08D, Zoetis Inc.
2 Poock S, Lucy M. Conception rate for postpartum dairy cows treated with different gonadorelin (GnRH) products for first or resynchronized timed AI. Presented at 2015 Midwest ADSA/ASAS Meeting, Des Moines, IA, March 16-18, 2015.
3 Caldwell V, Tison N, Martineau R, Dubuc J, Des Côteaux L. Non-inferiority randomized field clinical trial of two GnRH commercial products used in a systematic double-ovsynch protocol at first breeding in dairy cows, in Proceedings. Am Assoc Bov Pract Conf 2014.

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. All other trademarks are the property of their respective owners. Zoetis Inc. All rights reserved. FAC-00032